This is the authors' abstract. We don't add key points for this paper.
High Resolution Image Download MS PowerPoint Slide We report the discovery of an imidazopyridine series of IRAK1/4/pan-FLT3 kinase inhibitors. Optimization of this series has produced compound 31 which displays potent and selective inhibition of IRAK1, IRAK4, FLT3, and all mutant forms of FLT3, as well as good in vitro ADME and pharmacokinetic properties. In a mouse xenograft model of AML, 31 produces survival prolongation equal to that of Gilteritinib, the leading marketed FLT3 inhibitor currently used to treat AML.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hoyt et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: